In recent trading session, ImmunityBio Inc (NASDAQ:IBRX) saw 0.98 million shares changing hands at last check today with its beta currently measuring 0.74. Company’s recent per share price level of $2.65 trading at -$0.02 or -0.56% at last check today assigns it a market valuation of $1.94B. That most recent trading price of IBRX’s stock is at a discount of -297.36% from its 52-week high price of $10.53 and is indicating a premium of 1.51% from its 52-week low price of $2.61. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 8.81 million shares which gives us an average trading volume of 6.08 million if we extend that period to 3-months.
For ImmunityBio Inc (IBRX), analysts’ consensus is at an average recommendation of Sell while assigning it a mean rating of 1.67. Splitting up the data highlights that, out of 1 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 0 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.
ImmunityBio Inc (NASDAQ:IBRX) trade information
Upright in the red during last session for losing -0.56%, in the last five days IBRX remained trading in the red while hitting it’s week-highest on Monday, 12/16/24 when the stock touched $2.65 price level, adding 16.67% to its value on the day. ImmunityBio Inc’s shares saw a change of -47.11% in year-to-date performance and have moved -7.49% in past 5-day. ImmunityBio Inc (NASDAQ:IBRX) showed a performance of -45.54% in past 30-days. Number of shares sold short was 49.78 million shares which calculate 9.34 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 8 to the stock, which implies a rise of 66.88% to its recent value today. Analysts have been projecting 8 as a low price target for the stock while placing it at a high target of 8. It follows that stock’s current price would drop -201.89% in reaching the projected high whereas dropping to the targeted low would mean a loss of -201.89% for stock’s current value.
ImmunityBio Inc (IBRX) estimates and forecasts
Statistics highlight that ImmunityBio Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -63.83% of value to its shares in past 6 months, showing an annual growth rate of 7.07% while that of industry is 17.40. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 3,745.87% from the last financial year’s standing.
1 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 9.07M for the same. And 1 analysts are in estimates of company making revenue of 20.02M in the next quarter. Company posted 139k and 40k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 1.17% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 27.54% while estimates for its earnings growth in next 5 years are of -1.70%.
ImmunityBio Inc (NASDAQ:IBRX)’s Major holders
Insiders are in possession of 73.49% of company’s total shares while institution are holding 9.64 percent of that, with stock having share float percentage of 36.37%. Investors also watch the number of corporate investors in a company very closely, which is 9.64% institutions for ImmunityBio Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at IBRX for having 13.83 million shares of worth $87.42 million. And as of 2024-06-30, it was holding 2.0558 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 11.42 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.6978 of outstanding shares, having a total worth of $72.19 million.
